{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:44:51Z","timestamp":1790995491101,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":162,"publisher":"Springer US","isbn-type":[{"value":"9781071625729","type":"print"},{"value":"9781071625736","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-1-0716-2573-6_19","type":"book-chapter","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T16:06:13Z","timestamp":1662480373000},"page":"527-567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacogenetics of Drug Therapies in Rheumatoid Arthritis"],"prefix":"10.1007","author":[{"given":"Atinuke","family":"Aluko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabha","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"13","key":"19_CR1","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJM198503283121303","volume":"312","author":"ME Weinblatt","year":"1985","unstructured":"Weinblatt ME, Coblyn JS, Fox DA et al (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312(13):818\u2013822","journal-title":"N Engl J Med"},{"issue":"22","key":"19_CR2","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","volume":"343","author":"JM Bathon","year":"2000","unstructured":"Bathon JM, Martin RW, Fleischmann RM et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343(22):1586\u20131593","journal-title":"N Engl J Med"},{"issue":"1","key":"19_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13075-018-1544-9","volume":"20","author":"J Bluett","year":"2018","unstructured":"Bluett J, Sergeant JC, MacGregor AJ et al (2018) Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study. Arthritis Res Ther 20(1):50","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"19_CR4","first-page":"2532","volume":"59","author":"JH Hooijberg","year":"1999","unstructured":"Hooijberg JH, Broxterman HJ, Kool M et al (1999) Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59(11):2532\u20132535","journal-title":"Cancer Res"},{"issue":"2","key":"19_CR5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1182\/blood.V84.2.564.564","volume":"84","author":"JC Barredo","year":"1994","unstructured":"Barredo JC, Synold TW, Laver J et al (1994) Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 84(2):564\u2013569","journal-title":"Blood"},{"issue":"1","key":"19_CR6","first-page":"105","volume":"17","author":"J Galivan","year":"1980","unstructured":"Galivan J (1980) Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Pharmacol 17(1):105\u2013110","journal-title":"Mol Pharmacol"},{"issue":"17","key":"19_CR7","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1016\/0006-2952(79)90039-X","volume":"28","author":"DW Szeto","year":"1979","unstructured":"Szeto DW, Cheng YC, Rosowsky A et al (1979) Human thymidylate synthetase--III. Effects of methotrexate and folate analogs. Biochem Pharmacol 28(17):2633\u20132637","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"19_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/ar419","volume":"4","author":"ES Chan","year":"2002","unstructured":"Chan ES, Cronstein BN (2002) Molecular action of methotrexate in inflammatory diseases. Arthritis Res 4(4):266\u2013273","journal-title":"Arthritis Res"},{"issue":"11","key":"19_CR9","doi-asserted-by":"publisher","first-page":"8935","DOI":"10.1074\/jbc.M209578200","volume":"278","author":"L Rothem","year":"2003","unstructured":"Rothem L, Aronheim A, Assaraf YG (2003) Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells. J Biol Chem 278(11):8935\u20138941","journal-title":"J Biol Chem"},{"issue":"1","key":"19_CR10","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1074\/jbc.M309092200","volume":"279","author":"L Rothem","year":"2004","unstructured":"Rothem L, Stark M, Kaufman Y et al (2004) Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation. J Biol Chem 279(1):374\u2013384","journal-title":"J Biol Chem"},{"issue":"46","key":"19_CR11","doi-asserted-by":"publisher","first-page":"43873","DOI":"10.1074\/jbc.M208296200","volume":"277","author":"JR Whetstine","year":"2002","unstructured":"Whetstine JR, Witt TL, Matherly LH (2002) The human reduced folate carrier gene is regulated by the AP2 and sp1 transcription factor families and a functional 61-base pair polymorphism. J Biol Chem 277(46):43873\u201343880","journal-title":"J Biol Chem"},{"issue":"11","key":"19_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/00008571-200411000-00004","volume":"14","author":"T Dervieux","year":"2004","unstructured":"Dervieux T, Kremer J, Lein DO et al (2004) Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 14(11):733\u2013739","journal-title":"Pharmacogenetics"},{"issue":"3","key":"19_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2710.2009.01046.x","volume":"34","author":"H Hayashi","year":"2009","unstructured":"Hayashi H, Fujimaki C, Daimon T et al (2009) Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. J Clin Pharm Ther 34(3):355\u2013361","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"19_CR14","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer S, Burk O, von Richter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97(7):3473\u20133478","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"19_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1067\/mcp.2001.117412","volume":"70","author":"RB Kim","year":"2001","unstructured":"Kim RB, Leake BF, Choo EF et al (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70(2):189\u2013199","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"19_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/(SICI)1097-0215(19960301)65:5<613::AID-IJC10>3.0.CO;2-8","volume":"65","author":"MD Norris","year":"1996","unstructured":"Norris MD, De Graaf D, Haber M et al (1996) Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. Int J Cancer 65(5):613\u2013619","journal-title":"Int J Cancer"},{"issue":"2","key":"19_CR17","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1073\/pnas.88.2.547","volume":"88","author":"GH Mickisch","year":"1991","unstructured":"Mickisch GH, Merlino GT, Galski H et al (1991) Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci U S A 88(2):547\u2013551","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"19_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.5414\/CPP42496","volume":"42","author":"A Pawlik","year":"2004","unstructured":"Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I et al (2004) The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 42(9):496\u2013503","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"19_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2217\/pgs.15.150","volume":"17","author":"P Moya","year":"2016","unstructured":"Moya P, Salazar J, Arranz MJ et al (2016) Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients. Pharmacogenomics 17(1):25\u201329","journal-title":"Pharmacogenomics"},{"issue":"5","key":"19_CR20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/BF01799831","volume":"19","author":"R Rozen","year":"1996","unstructured":"Rozen R (1996) Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis 19(5):589\u2013594","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"19_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/ng0595-111","volume":"10","author":"P Frosst","year":"1995","unstructured":"Frosst P, Blom HJ, Milos R et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10(1):111\u2013113","journal-title":"Nat Genet"},{"issue":"5","key":"19_CR22","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1086\/301825","volume":"62","author":"NM van der Put","year":"1998","unstructured":"van der Put NM, Gabreels F, Stevens EM et al (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 62(5):1044\u20131051","journal-title":"Am J Hum Genet"},{"issue":"4","key":"19_CR23","first-page":"414","volume":"43","author":"SS Kang","year":"1988","unstructured":"Kang SS, Zhou J, Wong PW et al (1988) Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 43(4):414\u2013421","journal-title":"Am J Hum Genet"},{"issue":"2","key":"19_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/ard.58.2.79","volume":"58","author":"CJ Haagsma","year":"1999","unstructured":"Haagsma CJ, Blom HJ, van Riel PL et al (1999) Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 58(2):79\u201384","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"19_CR25","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1002\/1529-0131(200111)44:11<2525::AID-ART432>3.0.CO;2-B","volume":"44","author":"AE van Ede","year":"2001","unstructured":"van Ede AE, Laan RF, Blom HJ et al (2001) The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 44(11):2525\u20132530","journal-title":"Arthritis Rheum"},{"issue":"10","key":"19_CR26","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1136\/ard.2003.016337","volume":"63","author":"Y Berkun","year":"2004","unstructured":"Berkun Y, Levartovsky D, Rubinow A et al (2004) Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 63(10):1227\u20131231","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"19_CR27","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1002\/art.22129","volume":"54","author":"T Dervieux","year":"2006","unstructured":"Dervieux T, Greenstein N, Kremer J (2006) Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 54(10):3095\u20133103","journal-title":"Arthritis Rheum"},{"issue":"11","key":"19_CR28","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.2217\/14622416.8.11.1551","volume":"8","author":"M Kurzawski","year":"2007","unstructured":"Kurzawski M, Pawlik A, Safranow K et al (2007) 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics 8(11):1551\u20131559","journal-title":"Pharmacogenomics"},{"issue":"4","key":"19_CR29","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/art.21726","volume":"54","author":"JA Wessels","year":"2006","unstructured":"Wessels JA, de Vries-Bouwstra JK, Heijmans BT et al (2006) Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 54(4):1087\u20131095","journal-title":"Arthritis Rheum"},{"issue":"6","key":"19_CR30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/01.fpc.0000236326.80809.b1","volume":"17","author":"A Taniguchi","year":"2007","unstructured":"Taniguchi A, Urano W, Tanaka E et al (2007) Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet Genomics 17(6):383\u2013390","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"19_CR31","first-page":"1266","volume":"33","author":"SK Kim","year":"2006","unstructured":"Kim SK, Jun JB, El-Sohemy A et al (2006) Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 33(7):1266\u20131274","journal-title":"J Rheumatol"},{"issue":"5","key":"19_CR32","first-page":"728","volume":"28","author":"H Xiao","year":"2010","unstructured":"Xiao H, Xu J, Zhou X et al (2010) Associations between the genetic polymorphisms of MTHFR and outcomes of methotrexate treatment in rheumatoid arthritis. Clin Exp Rheumatol 28(5):728\u2013733","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"19_CR33","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/art.21573","volume":"54","author":"MH Weisman","year":"2006","unstructured":"Weisman MH, Furst DE, Park GS et al (2006) Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 54(2):607\u2013612","journal-title":"Arthritis Rheum"},{"issue":"4","key":"19_CR34","first-page":"572","volume":"35","author":"P Ranganathan","year":"2008","unstructured":"Ranganathan P, Culverhouse R, Marsh S et al (2008) Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 35(4):572\u2013579","journal-title":"J Rheumatol"},{"issue":"1","key":"19_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3109\/03009742.2011.617312","volume":"41","author":"R Caliz","year":"2012","unstructured":"Caliz R, del Amo J, Balsa A et al (2012) The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population. Scand J Rheumatol 41(1):10\u201314","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"19_CR36","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3899\/jrheum.080576","volume":"36","author":"MC Fisher","year":"2009","unstructured":"Fisher MC, Cronstein BN (2009) Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 36(3):539\u2013545","journal-title":"J Rheumatol"},{"issue":"2","key":"19_CR37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2165\/11531070-000000000-00000","volume":"30","author":"YH Lee","year":"2010","unstructured":"Lee YH, Song GG (2010) Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Clin Drug Investig 30(2):101\u2013108","journal-title":"Clin Drug Investig"},{"issue":"2","key":"19_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/tpj.2011.42","volume":"13","author":"SA Owen","year":"2013","unstructured":"Owen SA, Lunt M, Bowes J et al (2013) MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics J 13(2):137\u2013147","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"19_CR39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1247\/csf.20.191","volume":"20","author":"N Horie","year":"1995","unstructured":"Horie N, Aiba H, Oguro K et al (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5\u2032-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20(3):191\u2013197","journal-title":"Cell Struct Funct"},{"issue":"4B","key":"19_CR40","first-page":"3249","volume":"19","author":"K Kawakami","year":"1999","unstructured":"Kawakami K, Omura K, Kanehira E et al (1999) Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19(4B):3249\u20133252","journal-title":"Anticancer Res"},{"issue":"2","key":"19_CR41","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1158\/1078-0432.CCR-1198-03","volume":"10","author":"A DiPaolo","year":"2004","unstructured":"DiPaolo A, Chu E (2004) The role of thymidylate synthase as a molecular biomarker. Clin Cancer Res 10(2):411\u2013412","journal-title":"Clin Cancer Res"},{"issue":"1","key":"19_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/sj.tpj.6500012","volume":"1","author":"ST Pullarkat","year":"2001","unstructured":"Pullarkat ST, Stoehlmacher J, Ghaderi V et al (2001) Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1(1):65\u201370","journal-title":"Pharmacogenomics J"},{"issue":"18","key":"19_CR43","first-page":"6004","volume":"63","author":"K Kawakami","year":"2003","unstructured":"Kawakami K, Watanabe G (2003) Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 63(18):6004\u20136007","journal-title":"Cancer Res"},{"issue":"12","key":"19_CR44","first-page":"1381","volume":"9","author":"CM Ulrich","year":"2000","unstructured":"Ulrich CM, Bigler J, Velicer CM et al (2000) Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomark Prev 9(12):1381\u20131385","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"5","key":"19_CR45","first-page":"593","volume":"11","author":"K Kumagai","year":"2003","unstructured":"Kumagai K, Hiyama K, Oyama T et al (2003) Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 11(5):593\u2013600","journal-title":"Int J Mol Med"},{"key":"19_CR46","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.3389\/fphar.2018.01390","volume":"9","author":"S Lv","year":"2018","unstructured":"Lv S, Fan H, Li J et al (2018) Genetic polymorphisms of TYMS, MTHFR, ATIC, MTR, and MTRR are related to the outcome of methotrexate therapy for rheumatoid arthritis in a Chinese population. Front Pharmacol 9:1390","journal-title":"Front Pharmacol"},{"issue":"4","key":"19_CR47","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/0092-8674(94)90540-1","volume":"79","author":"CJ Sherr","year":"1994","unstructured":"Sherr CJ (1994) G1 phase progression: cycling on cue. Cell 79(4):551\u2013555","journal-title":"Cell"},{"issue":"5","key":"19_CR48","first-page":"1005","volume":"11","author":"DC Betticher","year":"1995","unstructured":"Betticher DC, Thatcher N, Altermatt HJ et al (1995) Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11(5):1005\u20131011","journal-title":"Oncogene"},{"issue":"21","key":"19_CR49","first-page":"7056","volume":"63","author":"F Lu","year":"2003","unstructured":"Lu F, Gladden AB, Diehl JA (2003) An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 63(21):7056\u20137061","journal-title":"Cancer Res"},{"issue":"18","key":"19_CR50","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1093\/jnci\/88.18.1269","volume":"88","author":"D Hochhauser","year":"1996","unstructured":"Hochhauser D, Schnieders B, Ercikan-Abali E et al (1996) Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. J Natl Cancer Inst 88(18):1269\u20131275","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"19_CR51","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00228-012-1341-3","volume":"69","author":"B Jekic","year":"2013","unstructured":"Jekic B, Lukovic L, Bunjevacki V et al (2013) Association of the TYMS 3G\/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients. Eur J Clin Pharmacol 69(3):377\u2013383","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"19_CR52","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1002\/art.20460","volume":"50","author":"T Dervieux","year":"2004","unstructured":"Dervieux T, Furst D, Lein DO et al (2004) Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 50(9):2766\u20132774","journal-title":"Arthritis Rheum"},{"issue":"5","key":"19_CR53","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1136\/ard.2009.111567","volume":"69","author":"PB Grabar","year":"2010","unstructured":"Grabar PB, Rojko S, Logar D et al (2010) Genetic determinants of methotrexate treatment in rheumatoid arthritis patients: a study of polymorphisms in the adenosine pathway. Ann Rheum Dis 69(5):931\u2013932","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"19_CR54","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1002\/art.22640","volume":"56","author":"JA Wessels","year":"2007","unstructured":"Wessels JA, van der Kooij SM, le Cessie S et al (2007) A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 56(6):1765\u20131775","journal-title":"Arthritis Rheum"},{"issue":"4","key":"19_CR55","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41397-018-0017-5","volume":"18","author":"R Lopez-Rodriguez","year":"2018","unstructured":"Lopez-Rodriguez R, Ferreiro-Iglesias A, Lima A et al (2018) Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis. Pharmacogenomics J 18(4):539\u2013545","journal-title":"Pharmacogenomics J"},{"issue":"10","key":"19_CR56","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/1529-0131(199810)41:10<1858::AID-ART19>3.0.CO;2-8","volume":"41","author":"JN Stolk","year":"1998","unstructured":"Stolk JN, Boerbooms AM, de Abreu RA et al (1998) Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 41(10):1858\u20131866","journal-title":"Arthritis Rheum"},{"issue":"3","key":"19_CR57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00008571-200403000-00006","volume":"14","author":"AM Marinaki","year":"2004","unstructured":"Marinaki AM, Ansari A, Duley JA et al (2004) Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14(3):181\u2013187","journal-title":"Pharmacogenetics"},{"issue":"1","key":"19_CR58","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1365-2125.2007.02985.x","volume":"65","author":"S Haglund","year":"2008","unstructured":"Haglund S, Taipalensuu J, Peterson C et al (2008) IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol 65(1):69\u201377","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"19_CR59","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/FTD.0b013e31820b42bb","volume":"33","author":"S Haglund","year":"2011","unstructured":"Haglund S, Vikingsson S, Soderman J et al (2011) The role of inosine-5\u2032-monophosphate dehydrogenase in thiopurine metabolism in patients with inflammatory bowel disease. Ther Drug Monit 33(2):200\u2013208","journal-title":"Ther Drug Monit"},{"issue":"5","key":"19_CR60","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/bcpt.13176","volume":"124","author":"A Citterio-Quentin","year":"2019","unstructured":"Citterio-Quentin A, El Mahmoudi A, Perret T, at al. (2019) Red blood cell IMPDH activity in adults and children with or without azathioprine: relationship between thiopurine metabolites, ITPA and TPMT activities. Basic Clin Pharmacol Toxicol 124(5):600\u2013606","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"19_CR61","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/00008571-199608000-00001","volume":"6","author":"EY Krynetski","year":"1996","unstructured":"Krynetski EY, Tai HL, Yates CR et al (1996) Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 6(4):279\u2013290","journal-title":"Pharmacogenetics"},{"issue":"4","key":"19_CR62","first-page":"694","volume":"58","author":"HL Tai","year":"1996","unstructured":"Tai HL, Krynetski EY, Yates CR et al (1996) Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 58(4):694\u2013702","journal-title":"Am J Hum Genet"},{"issue":"12","key":"19_CR63","doi-asserted-by":"publisher","first-page":"6444","DOI":"10.1073\/pnas.94.12.6444","volume":"94","author":"HL Tai","year":"1997","unstructured":"Tai HL, Krynetski EY, Schuetz EG et al (1997) Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A 94(12):6444\u20136449","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"19_CR64","doi-asserted-by":"publisher","first-page":"608","DOI":"10.7326\/0003-4819-126-8-199704150-00003","volume":"126","author":"CR Yates","year":"1997","unstructured":"Yates CR, Krynetski EY, Loennechen T et al (1997) Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126(8):608\u2013614","journal-title":"Ann Intern Med"},{"issue":"2","key":"19_CR65","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/hmg\/8.2.367","volume":"8","author":"MM Ameyaw","year":"1999","unstructured":"Ameyaw MM, Collie-Duguid ES, Powrie RH et al (1999) Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 8(2):367\u2013370","journal-title":"Hum Mol Genet"},{"issue":"2","key":"19_CR66","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/hmg\/8.2.371","volume":"8","author":"YY Hon","year":"1999","unstructured":"Hon YY, Fessing MY, Pui CH et al (1999) Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 8(2):371\u2013376","journal-title":"Hum Mol Genet"},{"issue":"8","key":"19_CR67","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1200\/JCO.2001.19.8.2293","volume":"19","author":"WE Evans","year":"2001","unstructured":"Evans WE, Hon YY, Bomgaars L et al (2001) Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 19(8):2293\u20132301","journal-title":"J Clin Oncol"},{"issue":"9","key":"19_CR68","doi-asserted-by":"publisher","first-page":"716","DOI":"10.7326\/0003-4819-129-9-199811010-00007","volume":"129","author":"AJ Black","year":"1998","unstructured":"Black AJ, McLeod HL, Capell HA et al (1998) Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 129(9):716\u2013718","journal-title":"Ann Intern Med"},{"issue":"1","key":"19_CR69","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/rheumatology\/keg028","volume":"42","author":"H Corominas","year":"2003","unstructured":"Corominas H, Domenech M, Laiz A et al (2003) Is thiopurine methyltransferase genetic polymorphism a major factor for withdrawal of azathioprine in rheumatoid arthritis patients? Rheumatology (Oxford) 42(1):40\u201345","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"19_CR70","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/0961203307085255","volume":"17","author":"U Boonsrirat","year":"2008","unstructured":"Boonsrirat U, Angsuthum S, Vannaprasaht S et al (2008) Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism. Lupus 17(2):132\u2013134","journal-title":"Lupus"},{"issue":"2","key":"19_CR71","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2217\/pgs.09.155","volume":"11","author":"JE Higgs","year":"2010","unstructured":"Higgs JE, Payne K, Roberts C et al (2010) Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 11(2):177\u2013188","journal-title":"Pharmacogenomics"},{"issue":"12","key":"19_CR72","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1373\/clinchem.2005.057158","volume":"51","author":"N von Ahsen","year":"2005","unstructured":"von Ahsen N, Armstrong VW, Behrens C et al (2005) Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin Chem 51(12):2282\u20132288","journal-title":"Clin Chem"},{"issue":"3","key":"19_CR73","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/FTD.0b013e31821a7c34","volume":"33","author":"M Shipkova","year":"2011","unstructured":"Shipkova M, Franz J, Abe M et al (2011) Association between adverse effects under azathioprine therapy and inosine triphosphate pyrophosphatase activity in patients with chronic inflammatory bowel disease. Ther Drug Monit 33(3):321\u2013328","journal-title":"Ther Drug Monit"},{"issue":"11","key":"19_CR74","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1097\/00008571-200411000-00010","volume":"14","author":"RB Gearry","year":"2004","unstructured":"Gearry RB, Roberts RL, Barclay ML et al (2004) Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 14(11):779\u2013781","journal-title":"Pharmacogenetics"},{"issue":"2","key":"19_CR75","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1124\/mol.106.025288","volume":"70","author":"BI Eklund","year":"2006","unstructured":"Eklund BI, Moberg M, Bergquist J et al (2006) Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol Pharmacol 70(2):747\u2013754","journal-title":"Mol Pharmacol"},{"issue":"1","key":"19_CR76","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/ibd.20004","volume":"13","author":"G Stocco","year":"2007","unstructured":"Stocco G, Martelossi S, Barabino A et al (2007) Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm Bowel Dis 13(1):57\u201364","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"19_CR77","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/MCG.0b013e31828b2866","volume":"48","author":"G Stocco","year":"2014","unstructured":"Stocco G, Cuzzoni E, De Iudicibus S et al (2014) Deletion of glutathione-s-transferase m1 reduces azathioprine metabolite concentrations in young patients with inflammatory bowel disease. J Clin Gastroenterol 48(1):43\u201351","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"19_CR78","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/art.1780380122","volume":"38","author":"PJ Kerstens","year":"1995","unstructured":"Kerstens PJ, Stolk JN, De Abreu RA et al (1995) Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum 38(1):142\u2013145","journal-title":"Arthritis Rheum"},{"issue":"10","key":"19_CR79","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1089\/gtmb.2018.0313","volume":"23","author":"J Yang","year":"2019","unstructured":"Yang J, Wang P, Qin Z et al (2019) NUDT15 and TPMT genetic polymorphisms are related to azathioprine intolerance in Chinese patients with rheumatic diseases. Genet Test Mol Biomarkers 23(10):751\u2013757","journal-title":"Genet Test Mol Biomarkers"},{"issue":"5","key":"19_CR80","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/cpt.1304","volume":"105","author":"MV Relling","year":"2019","unstructured":"Relling MV, Schwab M, Whirl-Carrillo M et al (2019) Clinical Pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther 105(5):1095\u20131105","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"19_CR81","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJM197309062891001","volume":"289","author":"KM Das","year":"1973","unstructured":"Das KM, Eastwood MA, McManus JP et al (1973) Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 289(10):491\u2013495","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"19_CR82","first-page":"54","volume":"32","author":"T Pullar","year":"2006","unstructured":"Pullar T, Capell HA (2006) Variables affecting efficacy and toxicity of sulphasalazine in rheumatoid arthritis. A review. Drugs 32(Suppl 1):54\u201357","journal-title":"Drugs"},{"issue":"1","key":"19_CR83","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1021\/mp050113v","volume":"3","author":"H Zaher","year":"2006","unstructured":"Zaher H, Khan AA, Palandra J et al (2006) Breast cancer resistance protein (Bcrp\/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm 3(1):55\u201361","journal-title":"Mol Pharm"},{"issue":"1","key":"19_CR84","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/sj.clpt.6100459","volume":"84","author":"Y Yamasaki","year":"2008","unstructured":"Yamasaki Y, Ieiri I, Kusuhara H et al (2008) Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther 84(1):95\u2013103","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"19_CR85","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/tpj.2013.45","volume":"14","author":"MD Wiese","year":"2014","unstructured":"Wiese MD, Alotaibi N, O'Doherty C et al (2014) Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. Pharmacogenomics J 14(4):350\u2013355","journal-title":"Pharmacogenomics J"},{"issue":"12","key":"19_CR86","first-page":"2492","volume":"29","author":"E Tanaka","year":"2002","unstructured":"Tanaka E, Taniguchi A, Urano W et al (2002) Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 29(12):2492\u20132499","journal-title":"J Rheumatol"},{"issue":"1","key":"19_CR87","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00008571-200002000-00005","volume":"10","author":"M Wadelius","year":"2000","unstructured":"Wadelius M, Stjernberg E, Wiholm BE et al (2000) Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. Pharmacogenetics 10(1):35\u201341","journal-title":"Pharmacogenetics"},{"issue":"1","key":"19_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5414\/CPP48001","volume":"48","author":"UD Kuhn","year":"2010","unstructured":"Kuhn UD, Anschutz M, Schmucker K et al (2010) Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics. Int J Clin Pharmacol Ther 48(1):1\u201310","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"19_CR89","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1038\/s41598-020-60467-8","volume":"10","author":"J Yee","year":"2020","unstructured":"Yee J, Kim SM, Han JM et al (2020) The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis. Sci Rep 10(1):3658","journal-title":"Sci Rep"},{"issue":"6","key":"19_CR90","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1002\/art.10308","volume":"46","author":"MC Genovese","year":"2002","unstructured":"Genovese MC, Bathon JM, Martin RW et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46(6):1443\u20131450","journal-title":"Arthritis Rheum"},{"issue":"9","key":"19_CR91","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9):1552\u20131563","journal-title":"Arthritis Rheum"},{"issue":"5","key":"19_CR92","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"EC Keystone","year":"2004","unstructured":"Keystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50(5):1400\u20131411","journal-title":"Arthritis Rheum"},{"issue":"1","key":"19_CR93","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/rheumatology\/kel175","volume":"46","author":"M Seitz","year":"2007","unstructured":"Seitz M, Wirthmuller U, Moller B et al (2007) The \u2212308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 46(1):93\u201396","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"19_CR94","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1080\/03009740410005863","volume":"33","author":"M Cuchacovich","year":"2004","unstructured":"Cuchacovich M, Ferreira L, Aliste M et al (2004) Tumour necrosis factor-alpha (TNF-alpha) levels and influence of \u2212308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rheumatol 33(4):228\u2013232","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"19_CR95","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1136\/ard.2009.117622","volume":"69","author":"S Pavy","year":"2010","unstructured":"Pavy S, Toonen EJ, Miceli-Richard C et al (2010) Tumour necrosis factor alpha \u2212308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 69(6):1022\u20131028","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"19_CR96","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3109\/s10165-012-0699-5","volume":"23","author":"Z Zeng","year":"2013","unstructured":"Zeng Z, Duan Z, Zhang T et al (2013) Association between tumor necrosis factor-alpha (TNF-alpha) promoter \u2212308 G\/A and response to TNF-alpha blockers in rheumatoid arthritis: a meta-analysis. Mod Rheumatol 23(3):489\u2013495","journal-title":"Mod Rheumatol"},{"issue":"22","key":"19_CR97","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1093\/hmg\/ddn245","volume":"17","author":"JR Maxwell","year":"2008","unstructured":"Maxwell JR, Potter C, Hyrich KL et al (2008) Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 17(22):3532\u20133538","journal-title":"Hum Mol Genet"},{"issue":"1","key":"19_CR98","first-page":"29","volume":"29","author":"M Fabris","year":"2002","unstructured":"Fabris M, Di Poi E, D'Elia A et al (2002) Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. J Rheumatol 29(1):29\u201333","journal-title":"J Rheumatol"},{"issue":"12","key":"19_CR99","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1002\/1529-0131(200112)44:12<2819::AID-ART469>3.0.CO;2-2","volume":"44","author":"C Morita","year":"2001","unstructured":"Morita C, Horiuchi T, Tsukamoto H et al (2001) Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis Rheum 44(12):2819\u20132827","journal-title":"Arthritis Rheum"},{"issue":"9","key":"19_CR100","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00296-008-0552-5","volume":"28","author":"A Ongaro","year":"2008","unstructured":"Ongaro A, De Mattei M, Pellati A et al (2008) Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis? Rheumatol Int 28(9):901\u2013908","journal-title":"Rheumatol Int"},{"issue":"4","key":"19_CR101","first-page":"701","volume":"29","author":"Y Vasilopoulos","year":"2011","unstructured":"Vasilopoulos Y, Bagiatis V, Stamatopoulou D et al (2011) Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-alpha response in rheumatoid arthritis. Clin Exp Rheumatol 29(4):701\u2013704","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"19_CR102","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1002\/art.20469","volume":"50","author":"LA Criswell","year":"2004","unstructured":"Criswell LA, Lum RF, Turner KN et al (2004) The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 50(9):2750\u20132756","journal-title":"Arthritis Rheum"},{"issue":"11","key":"19_CR103","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/art.1780301102","volume":"30","author":"PK Gregersen","year":"1987","unstructured":"Gregersen PK, Silver J, Winchester RJ (1987) The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30(11):1205\u20131213","journal-title":"Arthritis Rheum"},{"issue":"2","key":"19_CR104","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/sj.gene.6363738","volume":"2","author":"F Waldron-Lynch","year":"2001","unstructured":"Waldron-Lynch F, Adams C, Amos C et al (2001) Tumour necrosis factor 5\u2032 promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families. Genes Immun 2(2):82\u201387","journal-title":"Genes Immun"},{"issue":"3","key":"19_CR105","first-page":"676","volume":"59","author":"B Mulcahy","year":"1996","unstructured":"Mulcahy B, Waldron-Lynch F, McDermott MF et al (1996) Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. Am J Hum Genet 59(3):676\u2013683","journal-title":"Am J Hum Genet"},{"issue":"4","key":"19_CR106","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/art.20154","volume":"50","author":"A Martinez","year":"2004","unstructured":"Martinez A, Salido M, Bonilla G et al (2004) Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 50(4):1077\u20131082","journal-title":"Arthritis Rheum"},{"issue":"6","key":"19_CR107","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/ng.582","volume":"42","author":"EA Stahl","year":"2010","unstructured":"Stahl EA, Raychaudhuri S, Remmers EF et al (2010) Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42(6):508\u2013514","journal-title":"Nat Genet"},{"issue":"7","key":"19_CR108","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/art.27457","volume":"62","author":"J Cui","year":"2010","unstructured":"Cui J, Saevarsdottir S, Thomson B et al (2010) Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 62(7):1849\u20131861","journal-title":"Arthritis Rheum"},{"issue":"3","key":"19_CR109","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/art.33381","volume":"64","author":"D Plant","year":"2012","unstructured":"Plant D, Prajapati R, Hyrich KL et al (2012) Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum 64(3):665\u2013670","journal-title":"Arthritis Rheum"},{"issue":"8","key":"19_CR110","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/FPC.0b013e3283544043","volume":"22","author":"SB Krintel","year":"2012","unstructured":"Krintel SB, Palermo G, Johansen JS et al (2012) Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet Genomics 22(8):577\u2013589","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"19_CR111","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/FPC.0b013e328328d51f","volume":"19","author":"JD Bowes","year":"2009","unstructured":"Bowes JD, Potter C, Gibbons LJ et al (2009) Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenet Genomics 19(4):319\u2013323","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"19_CR112","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/ard.2010.133249","volume":"70","author":"LR Coulthard","year":"2011","unstructured":"Coulthard LR, Taylor JC, Eyre S et al (2011) Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis 70(1):98\u2013103","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"19_CR113","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1093\/hmg\/ddp177","volume":"18","author":"A Barton","year":"2009","unstructured":"Barton A, Eyre S, Ke X et al (2009) Identification of AF4\/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. Hum Mol Genet 18(13):2518\u20132522","journal-title":"Hum Mol Genet"},{"issue":"1","key":"19_CR114","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/gene.2008.82","volume":"10","author":"JP Hafler","year":"2009","unstructured":"Hafler JP, Maier LM, Cooper JD et al (2009) CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun 10(1):5\u201310","journal-title":"Genes Immun"},{"issue":"6","key":"19_CR115","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1136\/ard.2009.118406","volume":"69","author":"RJ Tan","year":"2010","unstructured":"Tan RJ, Gibbons LJ, Potter C et al (2010) Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann Rheum Dis 69(6):1029\u20131035","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"19_CR116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169956","volume":"12","author":"P Conigliaro","year":"2017","unstructured":"Conigliaro P, Ciccacci C, Politi C et al (2017) Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 genes are associated with the response to TNF inhibitors in patients with rheumatoid arthritis. PLoS One 12(1):e0169956","journal-title":"PLoS One"},{"issue":"3","key":"19_CR117","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/ard.2005.037150","volume":"65","author":"H Marotte","year":"2006","unstructured":"Marotte H, Pallot-Prades B, Grange L et al (2006) The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis 65(3):342\u2013347","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"19_CR118","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/ard.62.6.526","volume":"62","author":"L Padyukov","year":"2003","unstructured":"Padyukov L, Lampa J, Heimburger M et al (2003) Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 62(6):526\u2013529","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"19_CR119","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/ard.2004.027672","volume":"64","author":"H Schotte","year":"2005","unstructured":"Schotte H, Schluter B, Drynda S et al (2005) Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis 64(4):575\u2013581","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"19_CR120","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00296-012-2586-y","volume":"33","author":"I Jancic","year":"2013","unstructured":"Jancic I, Arsenovic-Ranin N, Sefik-Bukilica M et al (2013) 174G\/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. Rheumatol Int 33(6):1481\u20131486","journal-title":"Rheumatol Int"},{"issue":"6","key":"19_CR121","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100361","volume":"9","author":"J Sode","year":"2014","unstructured":"Sode J, Vogel U, Bank S et al (2014) Anti-TNF treatment response in rheumatoid arthritis patients is associated with genetic variation in the NLRP3-inflammasome. PLoS One 9(6):e100361","journal-title":"PLoS One"},{"issue":"10","key":"19_CR122","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139781","volume":"10","author":"J Sode","year":"2015","unstructured":"Sode J, Vogel U, Bank S et al (2015) Genetic variations in pattern recognition receptor loci are associated with anti-TNF response in patients with rheumatoid arthritis. PLoS One 10(10):e0139781","journal-title":"PLoS One"},{"issue":"7","key":"19_CR123","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1136\/ard.2009.117309","volume":"69","author":"C Potter","year":"2010","unstructured":"Potter C, Cordell HJ, Barton A et al (2010) Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis 69(7):1315\u20131320","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"19_CR124","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/tpj.2016.66","volume":"18","author":"J Sode","year":"2018","unstructured":"Sode J, Vogel U, Bank S et al (2018) Confirmation of an IRAK3 polymorphism as a genetic marker predicting response to anti-TNF treatment in rheumatoid arthritis. Pharmacogenomics J 18(1):81\u201386","journal-title":"Pharmacogenomics J"},{"key":"19_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.631603","volume":"12","author":"M Iwaszko","year":"2021","unstructured":"Iwaszko M, Wielinska J, Swierkot J et al (2021) IL-33 gene polymorphisms as potential biomarkers of disease susceptibility and response to TNF inhibitors in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis patients. Front Immunol 12:631603","journal-title":"Front Immunol"},{"issue":"9","key":"19_CR126","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/art.21266","volume":"52","author":"Z Tutuncu","year":"2005","unstructured":"Tutuncu Z, Kavanaugh A, Zvaifler N et al (2005) Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 52(9):2693\u20132696","journal-title":"Arthritis Rheum"},{"issue":"10","key":"19_CR127","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1136\/ard.2008.096982","volume":"68","author":"JD Canete","year":"2009","unstructured":"Canete JD, Suarez B, Hernandez MV et al (2009) Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 68(10):1547\u20131552","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"19_CR128","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1136\/ard.2007.086892","volume":"67","author":"S Tsukahara","year":"2008","unstructured":"Tsukahara S, Ikari K, Sato E et al (2008) A polymorphism in the gene encoding the Fcgamma IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67(12):1791\u20131792","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"19_CR129","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/art.22390","volume":"56","author":"A Kastbom","year":"2007","unstructured":"Kastbom A, Bratt J, Ernestam S et al (2007) Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum 56(2):448\u2013452","journal-title":"Arthritis Rheum"},{"issue":"9\u201310","key":"19_CR130","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2119\/2008-00056.Liu","volume":"14","author":"C Liu","year":"2008","unstructured":"Liu C, Batliwalla F, Li W et al (2008) Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 14(9\u201310):575\u2013581","journal-title":"Mol Med"},{"issue":"8","key":"19_CR131","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/annrheumdis-2012-202405","volume":"72","author":"M Umicevic Mirkov","year":"2013","unstructured":"Umicevic Mirkov M, Cui J, Vermeulen SH et al (2013) Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Ann Rheum Dis 72(8):1375\u20131381","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"19_CR132","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.4049\/jimmunol.167.7.3668","volume":"167","author":"M Martin","year":"2001","unstructured":"Martin M, Romero X, de la Fuente MA et al (2001) CD84 functions as a homophilic adhesion molecule and enhances IFN-gamma secretion: adhesion is mediated by Ig-like domain 1. J Immunol 167(7):3668\u20133676","journal-title":"J Immunol"},{"issue":"5","key":"19_CR133","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.4049\/jimmunol.171.5.2485","volume":"171","author":"SG Tangye","year":"2003","unstructured":"Tangye SG, Nichols KE, Hare NJ et al (2003) Functional requirements for interactions between CD84 and Src homology 2 domain-containing proteins and their contribution to human T cell activation. J Immunol 171(5):2485\u20132495","journal-title":"J Immunol"},{"issue":"3","key":"19_CR134","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003394","volume":"9","author":"J Cui","year":"2013","unstructured":"Cui J, Stahl EA, Saevarsdottir S et al (2013) Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet 9(3):e1003394","journal-title":"PLoS Genet"},{"issue":"7","key":"19_CR135","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2217\/pgs.13.60","volume":"14","author":"I Acosta-Colman","year":"2013","unstructured":"Acosta-Colman I, Palau N, Tornero J et al (2013) GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics 14(7):727\u2013734","journal-title":"Pharmacogenomics"},{"key":"19_CR136","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13075-016-0920-6","volume":"18","author":"K Honne","year":"2016","unstructured":"Honne K, Hallgrimsdottir I, Wu C et al (2016) A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis. Arthritis Res Ther 18:12","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"19_CR137","doi-asserted-by":"publisher","first-page":"e0213073","DOI":"10.1371\/journal.pone.0213073","volume":"14","author":"A Ferreiro-Iglesias","year":"2019","unstructured":"Ferreiro-Iglesias A, Montes A, Perez-Pampin E et al (2019) Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept. PLoS One 14(2):e0213073","journal-title":"PLoS One"},{"issue":"5","key":"19_CR138","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/tpj.2017.26","volume":"17","author":"S Bek","year":"2017","unstructured":"Bek S, Bojesen AB, Nielsen JV et al (2017) Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis. Pharmacogenomics J 17(5):403\u2013411","journal-title":"Pharmacogenomics J"},{"issue":"8","key":"19_CR139","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/rheumatology\/kez049","volume":"58","author":"EMA Hensor","year":"2019","unstructured":"Hensor EMA, McKeigue P, Ling SF et al (2019) Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. Rheumatology (Oxford) 58(8):1400\u20131409","journal-title":"Rheumatology (Oxford)"},{"issue":"16","key":"19_CR140","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2217\/pgs-2020-0043","volume":"21","author":"SS Gilani","year":"2020","unstructured":"Gilani SS, Nair N, Plant D et al (2020) Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score. Pharmacogenomics 21(16):1151\u20131156","journal-title":"Pharmacogenomics"},{"issue":"12","key":"19_CR141","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/art.41056","volume":"71","author":"Y Guan","year":"2019","unstructured":"Guan Y, Zhang H, Quang D et al (2019) Machine learning to predict anti-tumor necrosis factor drug responses of rheumatoid arthritis patients by integrating clinical and genetic markers. Arthritis Rheumatol 71(12):1987\u20131996","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"19_CR142","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jbspin.2011.10.007","volume":"79","author":"CI Daien","year":"2012","unstructured":"Daien CI, Fabre S, Rittore C et al (2012) TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis. Joint Bone Spine 79(5):471\u2013475","journal-title":"Joint Bone Spine"},{"issue":"2","key":"19_CR143","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/gene.2008.77","volume":"10","author":"MJ Coenen","year":"2009","unstructured":"Coenen MJ, Gregersen PK (2009) Rheumatoid arthritis: a view of the current genetic landscape. Genes Immun 10(2):101\u2013111","journal-title":"Genes Immun"},{"issue":"3","key":"19_CR144","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jbspin.2010.08.017","volume":"78","author":"MC Boissier","year":"2011","unstructured":"Boissier MC (2011) Cell and cytokine imbalances in rheumatoid synovitis. Joint Bone Spine 78(3):230\u2013234","journal-title":"Joint Bone Spine"},{"issue":"7","key":"19_CR145","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1016\/S0041-1345(02)03483-8","volume":"34","author":"Z Guo","year":"2002","unstructured":"Guo Z, Binswanger U, Knoflach A (2002) Role of codon 10 and codon 25 polymorphisms on TGF-beta 1 gene expression and protein synthesis in stable renal allograft recipients. Transplant Proc 34(7):2904\u20132906","journal-title":"Transplant Proc"},{"issue":"4","key":"19_CR146","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/rheumatology\/kes344","volume":"52","author":"A Ruyssen-Witrand","year":"2013","unstructured":"Ruyssen-Witrand A, Rouanet S, Combe B et al (2013) Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients. Rheumatology (Oxford) 52(4):636\u2013641","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"19_CR147","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/art.37707","volume":"65","author":"M Fabris","year":"2013","unstructured":"Fabris M, Quartuccio L, Vital E et al (2013) The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. Arthritis Rheum 65(1):88\u201397","journal-title":"Arthritis Rheum"},{"issue":"6","key":"19_CR148","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1136\/annrheumdis-2011-200337","volume":"71","author":"A Ruyssen-Witrand","year":"2012","unstructured":"Ruyssen-Witrand A, Rouanet S, Combe B et al (2012) Fcgamma receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 71(6):875\u2013877","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"19_CR149","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1136\/annrheumdis-2012-202435","volume":"73","author":"L Quartuccio","year":"2014","unstructured":"Quartuccio L, Fabris M, Pontarini E et al (2014) The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann Rheum Dis 73(4):716\u2013721","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"19_CR150","doi-asserted-by":"publisher","first-page":"e001524","DOI":"10.1136\/bmjopen-2012-001524","volume":"2","author":"A Kastbom","year":"2012","unstructured":"Kastbom A, Coster L, Arlestig L et al (2012) Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study. BMJ Open 2(5):e001524","journal-title":"BMJ Open"},{"issue":"2","key":"19_CR151","first-page":"189","volume":"31","author":"K Sarsour","year":"2013","unstructured":"Sarsour K, Greenberg J, Johnston JA et al (2013) The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-alpha antagonist therapies. Clin Exp Rheumatol 31(2):189\u2013194","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"19_CR152","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000485","volume":"3","author":"I Pal","year":"2017","unstructured":"Pal I, Szamosi S, Hodosi K et al (2017) Effect of Fcgamma-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis. RMD Open 3(2):e000485","journal-title":"RMD Open"},{"issue":"5","key":"19_CR153","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.autrev.2010.06.012","volume":"11","author":"M Fabris","year":"2012","unstructured":"Fabris M, Quartuccio L, Lombardi S et al (2012) The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun Rev 11(5):315\u2013320","journal-title":"Autoimmun Rev"},{"issue":"6","key":"19_CR154","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1136\/ard.2010.147199","volume":"70","author":"S Vosslamber","year":"2011","unstructured":"Vosslamber S, Raterman HG, van der Pouw Kraan TC et al (2011) Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis 70(6):1153\u20131159","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"19_CR155","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000448","volume":"3","author":"PA Juge","year":"2017","unstructured":"Juge PA, Gazal S, Constantin A et al (2017) Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis. RMD Open 3(2):e000448","journal-title":"RMD Open"},{"issue":"10","key":"19_CR156","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1136\/annrheumdis-2014-205539","volume":"73","author":"PA Juge","year":"2014","unstructured":"Juge PA, van Steenbergen HW, Constantin A et al (2014) SPP1 rs9138 variant contributes to the severity of radiological damage in anti-citrullinated protein autoantibody-negative rheumatoid arthritis. Ann Rheum Dis 73(10):1840\u20131843","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"19_CR157","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/tpj.2012.8","volume":"13","author":"J Wang","year":"2013","unstructured":"Wang J, Bansal AT, Martin M et al (2013) Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics J 13(3):235\u2013241","journal-title":"Pharmacogenomics J"},{"issue":"8","key":"19_CR158","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/FPC.0000000000000071","volume":"24","author":"C Enevold","year":"2014","unstructured":"Enevold C, Baslund B, Linde L et al (2014) Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis. Pharmacogenet Genomics 24(8):401\u2013405","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"19_CR159","first-page":"24","volume":"48","author":"X Liu","year":"2014","unstructured":"Liu X, Xu J, Hu CD et al (2014) The relationship between SNPs in the genes of TLR signal transduction pathway downstream elements and rheumatoid arthritis susceptibility. Tsitol Genet 48(3):24\u201329","journal-title":"Tsitol Genet"},{"issue":"1","key":"19_CR160","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/tpj.2016.88","volume":"18","author":"M Maldonado-Montoro","year":"2018","unstructured":"Maldonado-Montoro M, Canadas-Garre M, Gonzalez-Utrilla A et al (2018) Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis. Pharmacogenomics J 18(1):167\u2013172","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"19_CR161","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.21762","volume":"54","author":"P Ranganathan","year":"2006","unstructured":"Ranganathan P, McLeod H (2006) Methotrexate pharmacogenetics: first step toward individualized therapy in rheumatoid arthritis. Arthritis and Rheumatism 54(5):1366\u20131377","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"19_CR162","first-page":"279","volume":"2","author":"P Ranganathan","year":"2005","unstructured":"Ranganathan P (2005) Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis. Pharmacogenomics 2(4):279\u2013282","journal-title":"Pharmacogenomics"}],"container-title":["Methods in Molecular Biology","Pharmacogenomics in Drug Discovery and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2573-6_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T16:58:29Z","timestamp":1701017909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2573-6_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9781071625729","9781071625736"],"references-count":162,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2573-6_19","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"7 September 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}